Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI
Description
About Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI
The Human Squamous cell carcinoma antigen recognized by T-cells 3 Peptide (IEDB: 1715264) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Squamous cell carcinoma antigen recognized by T-cells Peptide, H-RLAEYQAYI-OH (Uniprot: Q15020 aa: 309-317) from JPT is produced under strict quality control and quality management.
Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI - Specifications
- Peptide sequence: H-RLAEYQAYI-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Prostate cancer, Adenocarcinoma
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI
References:
Read References with JPT’s Antigen Peptides
Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI has been described in:
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers., Cancer Sci, 2018 (PMID: 29938870)
Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer., Cancer Sci, 2004 (PMID: 14720331)
Documentation
Documentation for Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI
Properties
Properties of Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Adenocarcinoma, Prostate cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Protein Name: | Squamous cell carcinoma antigen recognized by T-cells |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Squamous cell carcinoma antigen recognized by T-cells 3 309-317, RLAEYQAYI
Information | Values |
---|---|
Sequence: | H-RLAEYQAYI-OH |
Specifications: | 9mer peptide as TFA salt |